Radium-223 dichloride was recently approved for the treatment of men with symptomatic castration-resistant prostate cancer without visceral disease. An understanding of when to use this first-in-class ...

本研究针对转移性去势抵抗性前列腺癌（mCRPC）骨转移患者，探讨镭-223（Ra-223）治疗的最佳时机及疗效影响因素。通过多中心回顾性分析发现，Ra-223可显著延长总生存期（OS至33.8个月），且既往多西他赛（DOC）治疗、骨转移灶≤5个、ALP≤260 U/L等因素与更好预后 ...

Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...

Magnetic resonance imaging (MRI) is not routinely performed before initiating radium-223 to document spinal epidural disease. However, radium-223 decays to form α-particles with very short path ...

本综述深入探讨了转移性去势抵抗性前列腺癌（mCRPC）的治疗策略，重点聚焦于两种核素药物——靶向骨转移灶的α粒子药物镭-223（Ra-223）与靶向前列腺特异性膜抗原（PSMA）的β粒子药物镥-177 vipivotide tetraxetan（177Lu-PSMA）的序贯应用。作者提出，对于多数首诊仅 ...

Radium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and ...

MUNICH — Details of the ERA 223 clinical trial that led to a restriction in Europe of the use of the radiopharmaceutical radium-223 dichloride (Ra-223; Xofigo, Bayer) have now been presented here at ...

MUNICH -- Men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) had worse outcomes when radium-223 (Xofigo) was added to abiraterone (Zytiga) and prednisone, according to ...

May 21, 2012 (Atlanta, Georgia) — In patients with bone metastases and castration-resistant prostate cancer (CRPC), radium-223 chloride (Ra-223) significantly prolonged overall survival and delayed ...

A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). This is an ...

Intratumoral and subcutaneous injection of HVJ-E (GEN0101) for metastatic castration-resistant prostate cancer: Open-label, phase I, dose escalation study. This is an ASCO Meeting Abstract from the ...

A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...